A5081929975- Glioma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- PARP inhibition in cancer therapy
- Ovarian cancer diagnosis and treatment
- Cannabis and Cannabinoid Research
- Cancer Immunotherapy and Biomarkers
- Cancer survivorship and care
- Colorectal Cancer Treatments and Studies
- Natural Compound Pharmacology Studies
- Toxin Mechanisms and Immunotoxins
- Cancer Research and Treatments
- Genetic factors in colorectal cancer
- Cancer Risks and Factors
- BRCA gene mutations in cancer
- Colorectal Cancer Surgical Treatments
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Complementary and Alternative Medicine Studies
- Metabolism, Diabetes, and Cancer
- Kidney Stones and Urolithiasis Treatments
- Advanced Breast Cancer Therapies
- Renal cell carcinoma treatment
- Electroconvulsive Therapy Studies
- Protein Degradation and Inhibitors
- Economic and Financial Impacts of Cancer
Mayo Clinic
2022-2025
Mayo Clinic in Arizona
2022-2024
Jacksonville College
2024
Mayo Clinic in Florida
2024
WinnMed
2024
Sutter Institute for Medical Research
2018-2023
Sutter Medical Center
2020-2022
Sutter Health
2021-2022
University of Chicago
2006
University of California, Davis
1992-2006
Standard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) to standard newly diagnosed glioblastoma.After surgery chemoradiotherapy, patients were randomized (2:1) receive temozolomide plus DCVax-L (n = 232) or placebo 99). Following recurrence, all allowed DCVax-L, without unblinding. The primary endpoint was progression free survival (PFS); secondary...
Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed.To investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to standard of care (SOC) extends survival among patients with glioblastoma.This phase 3, prospective, externally controlled nonrandomized trial compared overall (OS) in newly diagnosed (nGBM) recurrent (rGBM) treated DCVax-L plus SOC vs contemporaneous matched external...
PURPOSE Platinum-based chemotherapy is the standard of care for platinum-sensitive ovarian cancer, but complications from repeated platinum therapy occur. We assessed activity two all-oral nonplatinum alternatives, olaparib or olaparib/cediranib, versus platinum-based chemotherapy. PATIENTS AND METHODS NRG-GY004 an open-label, randomized, phase III trial conducted in United States and Canada. Eligible patients had high-grade serous endometrioid cancer. Patients were randomly assigned 1:1:1...
6003 Background: Combination cediranib (C) and olaparib (O) improved progression-free survival (PFS) in patients (pts) with relapsed platinum (plat)-sensitive high-grade ovarian cancer (ovca) compared to O alone a Phase 2 trial (NCT01116648). We conducted this randomized, open-label 3 (NCT02446600) assess whether combination C+O, or alone, was superior standard of care (SOC) plat-based therapy plat-sensitive ovca. Methods: Eligible pts had recurrent [ > 6-month plat-free interval (PFI)]...
PURPOSE The TAPUR Study is a pragmatic phase II basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers harboring potentially actionable genomic alterations. Data from two cohorts colorectal cancer (CRC) either ERBB2 amplifications or ERBB3 (ERBB2/3) mutations treated pertuzumab plus trastuzumab (P + T) are reported. METHODS Eligible measurable CRC were selected for treatment P T according to protocol-specified matching rules....
No AccessJournal of UrologyOriginal Articles1 Apr 1994Effect High Dose Vitamin C on Urinary Oxalate Levels Theodore R. Wandzilak, Stacy D. D'andre, Paul A. Davis, and Hibbard E. Williams WandzilakTheodore Wandzilak , D'andreStacy D'andre DavisPaul Davis WilliamsHibbard View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)35100-5AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail The effect high dose ascorbate...
132 Background: TAPUR is a phase II basket trial evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers genomic alterations. Results cohort CRC ERBB2 overexpression or amplification treated P+T are reported. Methods: Eligible had CRC, no standard treatment (tx) options, measurable disease, ECOG PS 0-2, and adequate organ function. Genomic testing was performed CLIA-certified, CAP-accredited site selected labs. Pts amplification, certain...
524 Background: Antiangiogenic tyrosine kinase inhibitors (TKIs) play a key role in treating renal cell carcinoma and other solid organ malignancies, but TKIs cause bothersome side effects that frequently necessitate dose reductions or treatment holds. Olanzapine has been useful for palliating symptoms from classical chemotherapies advanced cancer, its effect on TKI-related is largely unknown. This retrospective study aimed to estimate the efficacy of olanzapine TKI-induced nausea, vomiting,...
Chemotherapy-induced peripheral neuropathy is a common and often severe side effect from many chemotherapeutic agents, with limited treatment options. There no literature on the use of topical cannabinoids for chemotherapy-induced neuropathy.The current manuscript presents case series patients presenting in oncology clinics at Sutter Health, CA Mayo Clinic, Rochester, MN April 2019 to December 2020 who used creams containing delta-nine-tetrahydrocannabinol (THC) and/or cannabidiol (CBD).This...
The link between excess adiposity and carcinogenesis has been well established for multiple malignancies, cancer is one of the main contributors to obesity-related mortality. potential role different weight-loss interventions on risk modification assessed, however, its clinical implications remain be determined. In this review, we present data assessing effect weight loss risk. conducted a comprehensive search relevant literature using MEDLINE, Embase, Web Science, Google Scholar databases...
Background: There are limited evidence-based data to guide treatment recommendations for breast cancer (BC) patients ≥ 80 years (P80+). Identifying and addressing unmet needs critical. Aims: Advocate-BREAST80+ compared the of P80+ vs. < (P80-). Methods: In 12/2021, a REDCap survey was circulated electronically 6,918 persons enrolled in Mayo Clinic Breast Disease Registry. The asked about concerns satisfaction with multiple aspects BC care. Results: 2,437 participants responded (35 %...
Patients have been known to use cannabinoids for treating established chemotherapy-induced peripheral neuropathy (CIPN) based on anecdotal information and retrospective reports suggesting that such might be beneficial. In response, a double-blinded, placebo-controlled, randomized, pilot clinical trial was developed evaluate whether resultant data would support phase III testing cannabidiol (CBD) cream improve CIPN.
11565 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers genomic alterations. Results cohort STS CDK4 amplification treated P are reported. Methods: Eligible had STS, no standard treatment options, measurable disease, ECOG PS 0-2, and adequate organ function. Genomic testing was performed CLIA-certified, CAP-accredited site selected labs. Pts received at 125 mg orally once daily for 21 days,...
3595 Background: Ispinesib(SB-715992) is a polycyclic, nitrogen-containing heterocycle that inhibits the mitotic kinesin spindle protein (KSP). KSP essential for assembly and function during mitosis, rational target of anti-cancer therapy. This phase II study used two different dosing schedules; primary objective was to determine response rate (RR) secondary objectives were time tumor progression (TTP), free survival (PFS), overall (OS) toxicity. Methods: Patients (pts) randomized receive...
6043 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers genomic alterations. Results cohort HNC CDKN2A loss or mutation treated P are reported. Methods: Eligible had HNC, no standard treatment options, measurable disease, ECOG PS 0-2, and adequate organ function. Genomic testing was performed CLIA-certified, CAP-accredited site selected labs. Pts received at 125 mg orally once daily for 21 days,...
Abstract BACKGROUND Standard of care (SOC) and patient survival in glioblastoma have changed little the past 17 years. We evaluated a phase 3 trial whether adding an autologous tumor lysate-loaded dendritic cell vaccine (murcidencel) to SOC extends survival. Patients METHODS Newly diagnosed patients were randomized 2:1 either murcidencel or placebo. Under crossover design, all could receive following recurrence. All parties remained blinded regarding treatments before thus received at new...
TPS2085 Background: Glioblastoma (GBM) is the most common and aggressive form of brain tumor in adults. Despite maximal surgical resection, irradiation, chemotherapy, median overall survival (OS) remains at only 30 weeks for recurrent GBM (rGBM) patients, emphasizing need novel treatments. tumors are immunologically ‘cold,’ that they have an immune-suppressive microenvironment with a low number tumor-infiltrating lymphocytes (TIL). Interleukin 7 (IL-7) plays key role T cell development...
Abstract Disclosure: S. Fansa: None. W. Ghusn: E. Tama: B. Nicolalde: D. Anazco: D'Andre: Faubion: C. Shufelt: A. Acosta: M.D. Hurtado: Background: Aromatase inhibitors (AIs) block estrogen synthesis and are used as adjuvant treatment for breast cancer. AIs associated with weight gain that can lead to increased cardiometabolic risk, thereby affecting health survivorship quality in these patients. The role of anti-obesity medications (AOMs) patients using has not been studied. We sought...
Background: There are limited evidence-based data to guide treatment recommendations for breast cancer (BC) patients ≥80 years (P80+). Identifying and addressing unmet needs critical. Aims: Advocate-BREAST80+ compared the of P80+ vs. < 80 (P80−). Methods: In 12/2021, a REDCap survey was electronically circulated 6918 persons enrolled in Mayo Clinic Breast Disease Registry. The asked about concerns satisfaction with multiple aspects BC care. Results: Overall, 2437 participants responded...